The usage of spleen-derived mesenchymal stem cell for the treatment of pancreatitis in mice

• Main Authors: Chen-FangHuang, 黃千芳
• Other Authors: Yan-Shen Shan
• Format: Others
• Language: en_US
• Published: 2013
• Online Access: http://ndltd.ncl.edu.tw/handle/65488517657263981187

碩士 === 國立成功大學 === 臨床醫學研究所 === 101 === Pancreatitis is inflammation of the pancreas. It may be acute – beginning suddenly and lasting a few days, or chronic – occurring over many years. In recently years, new stem cell therapies have raised the possibility of improving pancreatitis treatment. And the mesenchymal stem cells (MSCs) are considered to play a role in tissue repair and regeneration, including have remarkable immunosuppressive properties. Otherwise, the possibility of the spleen being a reservoir of islet stem cells is supported by close interrelationships between the spleen and pancreas during development. In this study, we suppose that the mesenchymal stem cells from the spleen could have the ability to repair the damaged pancreatic cells after acute/chronic pancreatitis occurred by the way of differentiating into pancreatic cells or suppressing the inflammation to supply the pancreas function. In our research, we found that the MSCs present several MSCs specific surface markers. Then, in the cerulean-caused acute pancreatitis mouse model, the improvement of lipase and MPO activity level in the serum after the MSCs treatment was demonstrated and the labeled MSCs were also recognized in pancreas. And the edema level, necrosis level and amylase expression of pancreas in acute pancreatitis model were down-regulated after the MSCs treatment. Finally, the inflammatory cytokines TNF-α and IFN-γ mRNA expression were down-regulated and the anti-inflammatory cytokine IL-10 was up-regulated by MSCs treatment. In the other hand, we establish the other pancreatitis mouse model by surgery using the vessel champ to obstruct blood flow in a part of pancreas, and this part of pancreas will be ischemia. In this model, the cell loss in pancreas is supposed. As time goes by, the chronic pancreatitis could also be caused. Here we determined the IPGTT (Intraperitoneal Glucose Tolerance Test) on this surgery-caused pancreatitis model with or without MSCs treatment. The result revealed that the MSCs can successfully improve the IPGTT in pancreatitis. According to the above results, the abilities of MSCs to suppress the inflammation and repair the damaged tissue in acute pancreatitis model and pre-chronic pancreatitis model were already proved. So in the future, we are going to confirm that MSCs have the ability to repair pancreatitis not only by regulating inflammation but also by regenerating the pancreatic cells such as beta-cells and acinar cells.